|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Revenue from product sales | |||
| Cost of sales | |||
| Loss on non-hedge derivatives and other commodity contracts | |||
| Gross profit | |||
| Corporate administration, marketing and related expenses | |||
| Exploration and evaluation costs | |||
| Net impairment, derecognition of assets and profit (loss) on disposal | |||
| Reversal of impairment (impairment), (derecognition of assets) and profit (loss) on disposal | |||
| Net (impairment) reversal of impairment and net loss on disposal and derecognition of assets | |||
| Corporate restructuring costs | |||
| Other (expenses) income | |||
| Finance income | |||
| Foreign exchange and fair value adjustments | |||
| Finance costs and unwinding of obligations | |||
| Share of associates and joint ventures’ profit | |||
| Profit before taxation | |||
| Taxation | |||
| (Loss) profit for the year | |||
| Attributable to: | |||
| Equity shareholders | |||
| Non-controlling interests | |||
| Basic earnings (loss) per ordinary share (USD per share) | |||
| Diluted earnings (loss) per ordinary share (USD per share) |
Loading...
